How to Read an ISO 11737-2 Report Before You Buy: Sterility Testing as Part of Validation
Quick summary: ISO 11737-2:2019 governs tests of sterility performed while a sterilization process is being defined, validated or maintained. It is not a release testing standard. A report that names the edition, states the reduced exposure used, justifies the items and batches tested, records method suitability and explains how positive growth was investigated can go into a validation file.
A validation report arrives from a contract laboratory: forty pages, a results table, a conclusion, and one line stating that testing followed ISO 11737-2. The QA lead has an hour to decide whether that document supports the sterilization process being validated, and the sentence that matters is not the conclusion. It is the one describing what was exposed to the sterilizing agent.
ISO 11737-2 occupies a specific point in the sterilization life cycle, and knowing that point is what makes a report readable. The standard deals with tests of sterility run during development, validation and requalification, on product exposed to the sterilizing agent at a level reduced relative to routine processing. That sentence, from clause 1.1, tells a buyer what a report built on this standard should look like, and what it must never be used for.
What does ISO 11737-2 actually cover?
ISO 11737-2:2019 is the third edition, published in December 2019 and prepared by ISO technical committee TC 198. It cancels and replaces the second edition, ISO 11737-2:2009, which it revised. The 2019 text has no normative references and takes its vocabulary from ISO 11139:2018.
The scope is deliberately narrow. The standard specifies general criteria for tests of sterility on medical devices exposed to a treatment with the sterilizing agent that has been reduced relative to what is anticipated in routine processing, and those tests are intended to be performed when defining, validating or maintaining a sterilization process. In practice, the report you are reading describes a validation or requalification activity rather than a production run.
The body of the standard works through the operational questions a laboratory has to answer: how product is selected, how a sample item portion is defined when the whole product cannot be tested, how packaging is handled, which methods are used, how the method itself is assessed, and how that assessment is maintained. Annex B reproduces a table showing where typical responsibilities sit between a manufacturer and a laboratory, a useful page to have in a supplier meeting.
Which sterility tests does ISO 11737-2 exclude?
The exclusions are the most useful part of the standard for a buyer, because they draw the boundary suppliers sometimes blur. Clause 1.2 states that the document is not applicable to four activities.
| Excluded activity | Where it belongs instead | When a report cites ISO 11737-2 for it |
|---|---|---|
| Sterility testing for routine release of product that has been sterilized | The standard notes this is not a requirement of ISO 11135, ISO 11137-1, ISO 11137-2, ISO 14160, ISO 14937, ISO 17665-1 or ISO 20857 | Release rests on a validated process and its monitoring, not on a sterility test |
| Performing a test for sterility, and tests of or for sterility to demonstrate shelf life, stability or package integrity | Pharmacopoeial methods for the first; stability and packaging standards for the device and its sterile barrier system for the second | Two different operations are being described with similar words, or the report answers a different question than the buyer asked |
| Culturing of biological indicators or inoculated products | ISO 11138-7 for guidance on culturing biological indicators | Routine spore monitoring is being presented as validation microbiology |
The fourth row comes up constantly in facility conversations. A clinic running a biological indicator on every day a sterilizer is used is monitoring a process; a contract laboratory running tests of sterility on fractional exposures is validating one. Both produce microbiological results, and they belong to different standards and different audits.
What is the difference between a test of sterility and a test for sterility?
The standard defines the two phrases separately, and the difference is not cosmetic.
- A test of sterility is a technical operation performed as part of development, validation or requalification to determine the presence or absence of viable microorganisms on a product or portions of it, after exposure to the sterilizing agent at a reduced level.
- A test for sterility is a technical operation specified in a pharmacopoeia, performed on product following an aseptic process or exposure to a sterilization process.
Both definitions come from ISO 11139:2018, and the note attached to the definition of a test of sterility points out that the reduced exposure is what distinguishes it. When a document treats the two terms as interchangeable, the reader loses the clue that shows whether a result sits inside a validation or outside it.
Why is a sterility test on a fully sterilized lot not usable data?
The introduction to ISO 11737-2 holds the sentence that decides whether a report is worth anything. Product exposed to a terminal sterilization process in its final packaged form has a very low probability of a viable microorganism being present, on the order of one in a million, or 10⁻⁶. Because of that, the standard states that performing a test of sterility on product exposed to the complete sterilization process provides no scientifically usable data and is not recommended.
The reasoning is statistical. Sterilization kinetics follow an exponential relationship between surviving microorganisms and the extent of treatment, so the sterility of any single item cannot be assured and sterility is expressed as a probability. Testing a few units from a population with a contamination probability of one in a million is confirming arithmetic the validation already established, not measuring the process.
For a buyer, that becomes a screening rule. If a report claims to have verified sterility by testing finished, fully sterilized production lots against ISO 11737-2, it is describing something the standard recommends against. What it should describe is a fractional exposure, a verification dose, or the evaluation of naturally occurring bioburden, with product selected to represent routine production including packaging materials and processes.
What should an ISO 11737-2 report contain?
Clause 5 sets out what a laboratory has to justify, and the 2019 edition added a table clarifying which responsibilities sit with the manufacturer and which with the laboratory. The checklist below turns those requirements into questions a buyer can put in writing.
| What to look for | What it proves | Warning sign if absent |
|---|---|---|
| The edition of the standard followed | Whether the file reflects the 2019 text or the superseded 2009 edition | A citation without an edition, in a file read for years |
| The reduced exposure, fraction or verification dose applied | That a test of sterility was run rather than a release test | No exposure figure, with results reported as sterility |
| Number of items and batches, with a documented rationale | That sample selection was planned rather than convenient | A results table with no statement of items or batches |
| Product family rationale and how the sample item portion was chosen | That the item tested represents the family, and that bioburden distribution was known | A family claim with no inclusion criteria, or a portion taken from the easiest location |
| Method suitability result and the organisms used | That the method can recover and grow microorganisms at all | No suitability study, or one never repeated |
| Culture conditions, media and time in culture | That incubation matched the organisms the method must detect | Media and incubation described only as standard |
| Culture media immersion, with a rationale if not applied | That samples stayed in contact with media for the full period | Silence on immersion, for a product with internal channels |
| How positive growth was identified and investigated | That a recovery was treated as a finding rather than a footnote | A positive result with no identification or investigation |
| Controlled environment description and equipment calibration records | That the test was protected from adventitious contamination, on calibrated instruments | No environment description, or certificates requested after sign-off |
Two entries deserve their own sentence. Sample selection is a documented requirement: selection has to represent routine production including packaging, with a recorded rationale for any product family and a documented rationale for the number of items and batches. A results table with no rationale behind it is a set of numbers, not evidence. Method suitability is the other: without an assessment that the method allows microbial growth, a clean result is ambiguous, because it can mean the product was sterile or that something in the product suppressed the challenge organisms. Where a suitability test will not give an acceptable result, the 2019 text allows a reduction of inhibitory substances after multiple attempts, with a rationale and risk assessment.
What changed in the 2019 edition of ISO 11737-2?
The foreword lists the changes made to the text, and several of them change what a report should carry.
| Change in the third edition | Why it matters when reading a report |
|---|---|
| The interval between manufacture and exposure to the sterilizing agent is to be as short as possible | The report should show when product was made and when it was exposed |
| Guidance that packaging is not typically tested unless it is an integral part of the product | Packaging claims should be read against that boundary |
| Additional guidance on the controlled environment, and on method suitability results that are not acceptable | A reduced-inhibitor method can be accepted with a rationale and risk assessment; the environment description becomes part of the criteria |
| Guidance that microorganisms from positive growth should generally be identified, and on periodically demonstrating ongoing method suitability | A positive result without identification is an unfinished investigation, and an old suitability study cannot be assumed to describe the current method |
| A table clarifying typical responsibilities for the manufacturer and the laboratory | Responsibilities can be assigned in writing rather than assumed in a meeting |
That list explains why the edition matters when reading an older file. A validation written against the 2009 text can be complete by its own rules and still silent on points the 2019 edition covers. Where a supplier maintains a process across years, periodic demonstration of method suitability is one of the items a buyer is entitled to ask about, because it is the item designed to catch what small changes accumulate into.
How do I check a sterility testing laboratory before I buy?
Whether the laboratory is testing your product or a supplier's, four questions do most of the work.
- Which edition will the report cite? A laboratory that answers ISO 11737-2 without an edition is telling you how its reports are written.
- Is the method suitability current, and when is the next demonstration? A dated study with no plan for repeating it is a snapshot, not a maintained method.
- How will positive growth be identified and investigated? The standard expects identification in the general case, and a laboratory should describe the pathway before work begins.
It also helps to know which standards sit next to this one, because a validation package is rarely a single document. Bioburden estimation uses ISO 11737-1, bacterial endotoxin testing uses ISO 11737-3, and validation requirements for a specific process come from the modality standards: ISO 11135 for ethylene oxide, ISO 11137 for radiation, ISO 17665 for moist heat, ISO 20857 for dry heat, ISO 14160 for liquid chemical agents and ISO 14937 for processes not otherwise covered. The companion piece on ISO 11737-1 and -2 covers how bioburden fits alongside sterility testing, and the sterilization compliance hub collects the record-keeping side.
Documentation is where most facilities do their own work rather than buying it in. Traceability and records are covered in ISO 13485 and framed for risk in ISO 14971, while Health Canada maintains a list of recognized standards that manufacturers may draw on, alongside the federal framework in the Medical Devices Regulations. For a facility aligning its own monitoring records, a biological indicator 5-pack trial at CA $12.99 with shipping included is a low-commitment starting point, and the sterilization monitoring range covers the pouch, indicator and record side of the same workflow.
Ordering for a clinic, lab or care home? Wholesale and multi-site ordering covers case pricing and account setup, and the B2B wholesale collection lists the lines stocked for institutional buyers.
References and standards cited
- ISO 11737-2:2019, Microbiological methods — Part 2: Tests of sterility in the definition, validation and maintenance of a sterilization process (link checked 23 September 2026)
- ISO 11737-2:2019 online browsing platform entry (scope, terms and definitions) (link checked 23 September 2026)
- ISO 11737-1:2018, Microbiological methods — Part 1: Microorganism population on products (link checked 23 September 2026)
- ISO 11737-3:2023, Bacterial endotoxin testing (link checked 23 September 2026)
- ISO 11139:2018, Sterilization vocabulary (link checked 23 September 2026)
- ISO 11135:2014, Ethylene oxide sterilization — development, validation and routine control (link checked 23 September 2026)
- ISO 11137-1:2006, Radiation — Part 1: Requirements for development, validation and routine control (link checked 23 September 2026)
- ISO 11137-2:2013, Sterilization of health care products — Radiation — Part 2: Establishing the sterilization dose (link checked 23 September 2026)
- ISO 17665:2024, Moist heat sterilization requirements (link checked 23 September 2026)
- ISO 14937:2009, Sterilizing agents — development, validation and routine control (link checked 23 September 2026)
- ISO 14160:2020, Liquid chemical sterilizing agents for single-use medical devices (link checked 23 September 2026)
- ISO 20857:2010, Dry heat — Requirements for development, validation and routine control (link checked 23 September 2026)
- ISO 11138-7:2019, Biological indicators — selection, use and interpretation of results (link checked 23 September 2026)
- ISO 13485:2016, Medical devices — Quality management systems — Requirements for regulatory purposes (link checked 23 September 2026)
- ISO 14971:2019, Medical devices — Application of risk management to medical devices (link checked 23 September 2026)
- Health Canada, Medical devices (federal device framework) (link checked 23 September 2026)
- Health Canada, List of recognized standards for medical devices (link checked 23 September 2026)
- Medical Devices Regulations, SOR/98-282, Consolidation of Regulations (link checked 23 September 2026)
- Product Sterility Testing: To Test or Not to Test? Biomedical Instrumentation & Technology, 2016 (link checked 23 September 2026)
- Infections Associated with Resterilized Pacemakers and Defibrillators, NEJM, 2020 (link checked 23 September 2026)
- Measurlabs, sterility testing to ISO 11737-2 (aerobic, anaerobic and fungal) (link checked 23 September 2026)
Related Reading
- ISO 11737-1 and -2: Bioburden and Sterility Testing Explained
- ISO 11737-3: Bacterial Endotoxin Testing Explained
- Sterilization Modalities: ISO 17665, ISO 11135 and ISO 11137
- How to Validate Laboratory Waste Inactivation Before Disposal
- Sterilization compliance hub — records, indicators and audits
- Laboratory and diagnostic supply programme
- Biological indicator — 24-hour self-contained spore test, 25-pack
- Sterile centrifuge tubes, 15 mL, 500-case
- Laboratory consumables collection
- Wholesale and multi-site ordering desk
Frequently Asked Questions
What is ISO 11737-2?
ISO 11737-2:2019 is the part of the ISO 11737 microbiological methods series that specifies general criteria for tests of sterility on medical devices exposed to a sterilizing agent at a level reduced relative to routine processing. Those tests are performed when a sterilization process is being defined, validated or maintained.
Is ISO 11737-2 a release testing standard?
No. Its scope states that it is not applicable to sterility testing for routine release of product that has been subjected to a sterilization process, and it adds that release testing of that kind is not a requirement of ISO 11135, ISO 11137-1, ISO 11137-2, ISO 14160, ISO 14937, ISO 17665-1 or ISO 20857. A report that presents ISO 11737-2 as the basis for testing production lots on release has the framing wrong.
What is the difference between a test of sterility and a test for sterility?
The standard defines them separately. A test of sterility is a technical operation performed as part of development, validation or requalification to determine the presence or absence of viable microorganisms on a product or portions of it, after exposure to a reduced level of the sterilizing agent. A test for sterility is the pharmacopoeial operation performed on product after an aseptic process or after sterilization.
What does an ISO 11737-2 report have to include?
Expect the edition of the standard, the fractional exposure or verification dose applied, the number of items and batches with the rationale for that number, the product family rationale where one was used, how the sample item portion was chosen relative to bioburden distribution, the method suitability result, the culture conditions and how any positive growth was investigated.
What is a fractional exposure or verification dose?
It is the reduced treatment applied during validation, described in the standard's introduction as a treatment with the sterilizing agent reduced relative to that anticipated in routine processing. It exists to show the resistance of the contamination that occurs naturally on the product. Typical uses are establishing a sterilization dose for radiation and demonstrating the continued validity of an established dose.
What is method suitability in sterility testing?
Method suitability is a documented assessment showing that the test method itself allows microorganisms to grow, sometimes called a bacteriostasis and fungistasis test. It matters because residues, material chemistry or antimicrobial activity in the product can suppress growth and produce a false negative. The 2019 edition added guidance for results that are not acceptable, allowing a reduction of inhibitory substances with a rationale and risk assessment.
Does ISO 11737-2 cover culturing biological indicators?
No. Culturing of biological indicators or inoculated products is one of the activities the scope excludes, and the standard points readers to ISO 11138-7 for guidance on culturing biological indicators. Routine spore testing in a clinic is monitoring under a modality standard and a monitoring standard, not a test of sterility under ISO 11737-2.
How do I check a sterility testing laboratory before I buy?
Ask four questions before commissioning work: which edition the laboratory will report against, whether the method has a current suitability result on file and when it will next be demonstrated, which culture conditions and media will be used for your product, and how positive growth will be identified and investigated.
Last updated: September 2026. CliniEco Medical is a licensed medical device establishment (MDEL #35334).
0 commentaire